Importantly, PDX#62 characterized as resistant/refractory to cisplatin, harbours amplifications in multiple cancer-associated genes and increased expression of Cyclin E and MYCN42, known to be associated with resistance to platinum drugs. Here, CCNE1 is linked to cancer.